- Home
- MURA vs KZR Comparison
MURA vs KZR Comparison
Compare MURA & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MURA
- KZR
- Stock Information
- Founded
- MURA 2013
- KZR 2015
- Country
- MURA Ireland
- KZR United States
- Employees
- MURA N/A
- KZR N/A
- Industry
- MURA
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- MURA
- KZR Health Care
- Exchange
- MURA Nasdaq
- KZR Nasdaq
- Market Cap
- MURA 62.2M
- KZR 65.3M
- IPO Year
- MURA N/A
- KZR 2018
- Fundamental
- Price
- MURA $3.49
- KZR $7.53
- Analyst Decision
- MURA Strong Buy
- KZR Hold
- Analyst Count
- MURA 4
- KZR 2
- Target Price
- MURA $16.00
- KZR $20.00
- AVG Volume (30 Days)
- MURA 50.8K
- KZR 60.4K
- Earning Date
- MURA 11-13-2024
- KZR 11-12-2024
- Dividend Yield
- MURA N/A
- KZR N/A
- EPS Growth
- MURA N/A
- KZR N/A
- EPS
- MURA N/A
- KZR N/A
- Revenue
- MURA N/A
- KZR N/A
- Revenue This Year
- MURA N/A
- KZR N/A
- Revenue Next Year
- MURA N/A
- KZR $66.68
- P/E Ratio
- MURA N/A
- KZR N/A
- Revenue Growth
- MURA N/A
- KZR N/A
- 52 Week Low
- MURA $2.88
- KZR $5.20
- 52 Week High
- MURA $6.25
- KZR $11.40
- Technical
- Relative Strength Index (RSI)
- MURA 51.24
- KZR 49.59
- Support Level
- MURA $3.31
- KZR $7.27
- Resistance Level
- MURA $3.66
- KZR $7.50
- Average True Range (ATR)
- MURA 0.17
- KZR 0.48
- MACD
- MURA -0.01
- KZR -0.08
- Stochastic Oscillator
- MURA 54.55
- KZR 40.00
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.